Protalix BioTherapeutics, Inc. (NYSE MKT: PLX) shares inched up 0.1% to 62 cents, on giving an oral presentation highlighting the results of the phase I/II clinical trial of PRX-102 for the treatment of Fabry disease at a symposium in Rome. Share volume was 160,000, compared to an all-day average of 119,000